Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
At the upcoming Visual Studio Live! Las Vegas developer conference, SQL expert Denny Cherry will share essential indexing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback